Literature DB >> 15010696

Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release.

Houman Homayoun1, Mark R Stefani, Barbara W Adams, Gilles D Tamagan, Bita Moghaddam.   

Abstract

Pharmacological manipulation of N-methyl-D-aspartate (NMDA) receptors may be critical for the treatment of many neurological and psychiatric disorders. Metabotropic glutamate (mGlu5) receptors are abundant in corticolimbic circuitry, where they modulate NMDA receptor-mediated signal transduction. Therefore, pharmacological manipulation of mGlu5 receptor may provide a treatment strategy for cognitive disorders that are associated with NMDA receptor dysfunction. We sought to determine whether the recently described molecular and cellular interactions between NMDA and mGlu5 receptors coregulate higher order behaviors. We examined the interaction of the selective mGlu5 receptor antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and the use-dependent NMDA antagonist MK-801, on locomotion, stereotypy, working memory, instrumental learning, and corticolimbic dopamine release. MPEP, at 10 mg/kg, but not 3 mg/kg, impaired working memory and instrumental learning, transiently increased dopamine release in prefrontal cortex and nucleus accumbens, and augmented the effect of MK-801 on cortical dopamine release, locomotion, and stereotypy. Pretreatment with 3 mg/kg of MPEP enhanced the detrimental effects of MK-801 on cognition. These results demonstrate that an mGlu5 receptor antagonist can potentiate the motoric, cognitive, and dopaminergic effects of an NMDA receptor antagonist. Thus, mGlu5 receptors appear to play a major role in regulating NMDA receptor-dependent cognitive functions such as learning and working memory. By extension, these results suggest that pharmacological potentiation of mGlu5 receptors may ameliorate the cognitive and other behavioral abnormalities associated with NMDA receptor deficiency. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15010696     DOI: 10.1038/sj.npp.1300417

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  103 in total

1.  Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.

Authors:  Alice L Rodriguez; Mark D Grier; Carrie K Jones; Elizabeth J Herman; Alexander S Kane; Randy L Smith; Richard Williams; Ya Zhou; Joy E Marlo; Emily L Days; Tasha N Blatt; Satyawan Jadhav; Usha N Menon; Paige N Vinson; Jerri M Rook; Shaun R Stauffer; Colleen M Niswender; Craig W Lindsley; C David Weaver; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2010-10-05       Impact factor: 4.436

2.  Interaction of blockers of ionotropic NMDA receptors and metabotropic glutamate receptors in a working memory test in rats.

Authors:  Y A Novitskaya; O A Dravolina; E E Zvartau; W Danysz; A Y Bespalov
Journal:  Neurosci Behav Physiol       Date:  2010-07-17

Review 3.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Brain Res Bull       Date:  2010-04-24       Impact factor: 4.077

4.  Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade.

Authors:  Mark R Stefani; Bita Moghaddam
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

Review 5.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

6.  Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.

Authors:  Robert W Gould; Russell J Amato; Michael Bubser; Max E Joffe; Michael T Nedelcovych; Analisa D Thompson; Hilary H Nickols; Johannes P Yuh; Xiaoyan Zhan; Andrew S Felts; Alice L Rodriguez; Ryan D Morrison; Frank W Byers; Jerri M Rook; John S Daniels; Colleen M Niswender; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2015-08-28       Impact factor: 7.853

7.  Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.

Authors:  Nathalie Turle-Lorenzo; Nathalie Breysse; Christelle Baunez; Marianne Amalric
Journal:  Psychopharmacology (Berl)       Date:  2005-02-22       Impact factor: 4.530

8.  Functional interaction of mGlu5 and NMDA receptors in aversive learning in rats.

Authors:  S W Fowler; A K Ramsey; J M Walker; P Serfozo; M F Olive; T R Schachtman; A Simonyi
Journal:  Neurobiol Learn Mem       Date:  2010-11-17       Impact factor: 2.877

9.  Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling.

Authors:  Hong Wang; Linda Westin; Yi Nong; Shari Birnbaum; Jacob Bendor; Hjalmar Brismar; Eric Nestler; Anita Aperia; Marc Flajolet; Paul Greengard
Journal:  Science       Date:  2009-12-11       Impact factor: 47.728

10.  Novel mGluR5 positive allosteric modulator improves functional recovery, attenuates neurodegeneration, and alters microglial polarization after experimental traumatic brain injury.

Authors:  David J Loane; Bogdan A Stoica; Flaubert Tchantchou; Alok Kumar; James P Barrett; Titilola Akintola; Fengtian Xue; P Jeffrey Conn; Alan I Faden
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.